ACM Biolabs Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.87M

  • Investors
  • 7

ACM Biolabs General Information

Description

Operator of a biotechnology company intended to develop novel vaccines using proprietary artificial cell membrane technology. The company develops prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment, enabling medical researchers to develop effective vaccines.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 71 Nanyang Drive
  • Suite 02M-02 NTU Innovation Centre
  • Singapore, 638075
  • Singapore
+65 6265
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 71 Nanyang Drive
  • Suite 02M-02 NTU Innovation Centre
  • Singapore, 638075
  • Singapore
+65 6265

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ACM Biolabs Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 08-May-2025 $2.87M Completed Clinical Trials - Phase 1
8. Later Stage VC (Series B1) 20-Sep-2022 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B) 19-Aug-2021 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series A1) 14-Jan-2021 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series A) 03-Mar-2020 Completed Pre-Clinical Trials
4. Seed Round 01-Jul-2015 Completed Pre-Clinical Trials
3. Accelerator/Incubator Completed Pre-Clinical Trials
2. Spin-Off 26-Jun-2013 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2013 Completed Pre-Clinical Trials
To view ACM Biolabs’s complete valuation and funding history, request access »

ACM Biolabs Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B1
Series B
Series A1
Series A 652,100 $4 $4 1x $4 8.1%
Seed 1,024,291 $2.71 $2.71 1x $2.71 12.72%
To view ACM Biolabs’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ACM Biolabs Patents

ACM Biolabs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023226175-A1 Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof Pending 23-Feb-2022
EP-4482477-A1 Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof Pending 23-Feb-2022
US-20250235532-A1 Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof Pending 23-Feb-2022
WO-2023161378-A1 Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof Inactive 23-Feb-2022
AU-2022258552-A1 Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof Pending 12-Apr-2021 A61K9/1273
To view ACM Biolabs’s complete patent history, request access »

ACM Biolabs Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ACM Biolabs Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Coalition for Epidemic Preparedness Innovations Impact Investing Minority
Nagase Future Investments Corporate Venture Capital Minority
RITZ Venture Capital Venture Capital Minority
Shenzhen Yifeng Investment Management Enterprise Venture Capital Minority
San Pacific Investments Family Office Minority
You’re viewing 5 of 7 investors. Get the full list »

ACM Biolabs Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
ACM Biosciences Basel, Switzerland 2020

ACM Biolabs FAQs

  • When was ACM Biolabs founded?

    ACM Biolabs was founded in 2013.

  • Where is ACM Biolabs headquartered?

    ACM Biolabs is headquartered in Singapore, Singapore.

  • What is the size of ACM Biolabs?

    ACM Biolabs has 19 total employees.

  • What industry is ACM Biolabs in?

    ACM Biolabs’s primary industry is Drug Discovery.

  • Is ACM Biolabs a private or public company?

    ACM Biolabs is a Private company.

  • What is ACM Biolabs’s current revenue?

    The current revenue for ACM Biolabs is .

  • How much funding has ACM Biolabs raised over time?

    ACM Biolabs has raised $26M.

  • Who are ACM Biolabs’s investors?

    Coalition for Epidemic Preparedness Innovations, Nagase Future Investments, RITZ Venture Capital, Shenzhen Yifeng Investment Management Enterprise, and San Pacific Investments are 5 of 7 investors who have invested in ACM Biolabs.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process